Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Hepatology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.27490PMID 25251399
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

  2014cited by this paper
• Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk

  2014influential reference
• TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content

  2014cited by this paper
• Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

  2014influential reference
• Comparison of Liver Fat Indices for the Diagnosis of Hepatic Steatosis and Insulin Resistance

  2014cited by this paper
• PNPLA3 mediates hepatocyte triacylglycerol remodeling[S]

  2014cited by this paper
• Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease

  2014cited by this paper
• Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

  2013cited by this paper
• A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia

  2013cited by this paper
• PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease

  2013cited by this paper
• Desmosterol in human nonalcoholic steatohepatitis

  2013cited by this paper
• Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

  2013cited by this paper
• Genetic Variation at NCAN Locus Is Associated with Inflammation and Fibrosis in Non-Alcoholic Fatty Liver Disease in Morbid Obesity

  2013cited by this paper
• Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

  2013cited by this paper
• Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis.

  2013cited by this paper
• Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.

  2012cited by this paper
• Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.

  2012cited by this paper
• Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits

  2011cited by this paper
• The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver.

  2011cited by this paper
• Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

  2011cited by this paper
• Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

  2011cited by this paper
• Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review

  2011cited by this paper
• I148M patatin‐like phospholipase domain‐containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease

  2010cited by this paper
• Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

  2010influential reference
• Ethnic differences in hepatic steatosis: An insulin resistance paradox?

  2009cited by this paper
• Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.

  2008cited by this paper
• Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease.

  2008influential reference
• Carotid artery intima-media thickness in nonalcoholic fatty liver disease.

  2008influential reference
• Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

  2008cited by this paper
• Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.

  2008influential reference
• Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

  2008cited by this paper
• Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis

  2007cited by this paper
• From fat to inflammation.

  2006cited by this paper
• Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis.

  2006cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

  2002cited by this paper
• Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

  2001cited by this paper

• Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort

  2026cites this paper
• A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation.

  2026cites this paper
• Genetic Analysis of Metabolic-associated Steatosis Liver Disease in a Colombian Cohort.

  2025cites this paper
• Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk

  2025cites this paper
• Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review

  2025cites this paper
• Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention

  2025cites this paper
• Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine.

  2025cites this paper
• The Basics of Metabolic Dysfunction-Associated Steatotic Liver Disease for Cardiologists: Pathophysiology, Diagnosis, and Treatment.

  2025cites this paper
• Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD

  2025cites this paper
• Decoding the triglyceride-glucose index in metabolic dysfunction-associated steatotic liver disease: integrative insights from Mendelian randomization, cross-tissue transcriptomics, and spatial multi-omics

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, model and treatment (Review)

  2025cites this paper
• Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease

  2025cites this paper
• Cause-specific mortality in lean individuals with metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• Метаболически ассоциированная жировая болезнь печени у детей: современное состояние и перспективы на будущее

  2025cites this paper
• MetALD: Genetic Factors and Clinical Outcomes

  2025cites this paper
• EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis.

  2025cites this paper
• Cardiovascular Manifestations of Patients with Non-Alcoholic Fatty Liver Disease

  2025cites this paper
• Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism

  2025cites this paper
• AASLD Practice Statement on the evaluation and management of metabolic dysfunction-associated steatotic liver disease in children.

  2025cites this paper
• Mitochondria at the Crossroads: Linking the Mediterranean Diet to Metabolic Health and Non-Pharmacological Approaches to NAFLD

  2025cites this paper
• Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis

  2025cites this paper
• Identification of biomarkers between coronary artery disease and non-alcoholic steatohepatitis: a combination of bioinformatics and machine learning

  2025cites this paper
• DPP4 rs17574 polymorphism and elevated DPP4 levels linked to fatty liver in subclinical atherosclerosis: GEA study findings

  2025cites this paper
• Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease.

  2025cites this paper
• Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study

  2024cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV—Limitations on Antiretroviral Therapy Selection

  2024cites this paper
• Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?

  2024cites this paper
• Biosynthesis and Metabolism of ApoB-Containing Lipoproteins.

  2024cites this paper
• Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)

  2024cites this paper
• Gut microbiota in MAFLD: therapeutic and diagnostic implications

  2024cites this paper
• Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies.

  2024cites this paper
• Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?

  2024cites this paper
• An Insight into the Genetic Predisposition of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Africa

  2024cites this paper
• Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

  2024cites this paper
• Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach

  2024cites this paper
• Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies

  2024cites this paper
• Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus

  2024cites this paper
• Drug repurposing in MASLD and MASH-cirrhosis: Targets and treatment approaches based on pathways analysis.

  2024cites this paper
• NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay

  2024cites this paper
• Immunological dynamics in MASH: from landscape analysis to therapeutic intervention

  2024cites this paper
• Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?

  2024cites this paper
• Decoding 17-Beta-hydroxysteroid Dehydrogenase 13: A Multifaceted Perspective on Its Role in Hepatic Steatosis and Associated Disorders

  2024cites this paper
• Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD

  2024cites this paper
• Metabolism and Clinical Significance of Triglycerides

  2024cites this paper
• Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease

  2024cites this paper
• Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease

  2024cites this paper
• Lipid metabolism in MASLD and MASH: From mechanism to the clinic

  2024cites this paper
• TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

  2024cites this paper
• MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges

  2024cites this paper
• From MASH to HCC: the role of Gas6/TAM receptors

  2024cites this paper
• PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

  2024cites this paper
• Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease

  2024cites this paper
• Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease.

  2024cites this paper
• Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances

  2024cites this paper
• Dysfunctional VLDL metabolism in MASLD

  2024cites this paper
• Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity

  2024cites this paper
• TM6SF2-rs58542926 genotype has opposing effects on incidence of hepatic and cardiac events in a community cohort: TM6SF2 effects on liver and cardiac outcomes.

  2024cites this paper
• Influence of nonalcoholic fatty liver disease severity on carotid adventitial vasa vasorum

  2024cites this paper
• Novel insights into metabolic‐associated steatotic liver disease preclinical models

  2024cites this paper
• Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future.

  2024cites this paper
• Parental History of Type 2 Diabetes Mellitus and PNPLA3 Polymorphism Increase the Risk of Severe Stages of Nonalcoholic Fatty Liver Disease

  2023cites this paper
• Deciphering the liver enigma: distinguishing drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease—a comprehensive narrative review

  2023cites this paper
• Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.

  2023cites this paper
• Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean

  2023cites this paper
• Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease

  2023cites this paper
• Associations between metabolic hyperferritinaemia, fibrosis‐promoting alleles and clinical outcomes in steatotic liver disease

  2023cites this paper
• The mitochondrial amidoxime reducing component—from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target

  2023cites this paper
• Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors

  2023influential citation
• Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women

  2023cites this paper
• From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention

  2023cites this paper
• Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis

  2023cites this paper
• Large-scale identification of undiagnosed hepatic steatosis using natural language processing

  2023cites this paper
• Liver fibrosis assessed using non-invasive markers and genetic polymorphisms (PNPLA3 and TM6SF2) predisposing to liver fibrosis, is associated with hospitalization or death from heart failure: a prospective UK Biobank study

  2023cites this paper
• Impact of fibrosis on liver‐related event incidence in nonalcoholic fatty liver disease: A multicenter observational study

  2023cites this paper
• Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades.

  2023cites this paper
• Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity

  2023cites this paper
• Mitochondrial dynamics in health and disease: mechanisms and potential targets

  2023cites this paper
• Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)

  2023cites this paper
• Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key

  2023cites this paper
• PNPLA3 rs738409 Genetic Variant Inversely Correlates with Platelet Count, Thereby Affecting the Performance of Noninvasive Scores of Hepatic Fibrosis

  2023cites this paper
• TM6SF2 reduces lipid accumulation in vascular smooth muscle cells by inhibiting LOX-1 and CD36 expression.

  2023cites this paper
• Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level

  2023cites this paper
• Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.

  2023cites this paper
• Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• No association of NAFLD-related polymorphisms in PNPLA3 and TM6SF2 with all-cause and cardiovascular mortality in an Austrian population study

  2023cites this paper
• Advances in the genetics of nonalcoholic fatty liver disease

  2023cites this paper
• Cholesterol-associated Locus EHBP1 Protects against NASH Fibrosis

  2023cites this paper
• Hepatic COX1 loss leads to impaired autophagic flux and exacerbates nonalcoholic steatohepatitis

  2023cites this paper
• Genetic Markers Predisposing to Nonalcoholic Steatohepatitis.

  2023cites this paper
• Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases

  2023cites this paper
• The impact of transmembrane 6 superfamily 2 (TM6SF2) rs58542926 on liver-related events in patients with advanced chronic liver disease.

  2023cites this paper
• Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association

  2023cites this paper
• Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease.

  2023cites this paper
• Correlation between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction in non-obese adults: a cross-sectional study

  2023cites this paper
• Concise review of lipidomics in nonalcoholic fatty liver disease.

  2023cites this paper
• MAFLD: a multisystem disease

  2023cites this paper